New primary monoclonal antibodies · 30. October 2021

Benefit from natural in-vivo maturation to get access to highly specific and high affinity rat monoclonal antibodies for therapeutic use targeting transmembrane proteins GPCR, ion channels and other complex epitopes

GPCR therapeutic monoclonal antibodies  · 11. September 2021

SYnAbs unique therapeutic effector monoclonal antibodies targeting anaphylatoxin C3aR and C5aR GPCR. Functional antibody targeting complex transmembrane proteins and G protein-coupled receptors.

Membrane functional antibodies : depleting, blocking, neutralizing, agonist and antagonist · 21. August 2021

SYnAbs generates innovative functional monoclonals against clusters of differentiation markers, IgG superfamily, and C-type lectin-like receptors (CLRs). Discover how SYnAbs generate Siplizumab anti-human CD2a antibody and other transmembrane effector monoclonals.

GPCR therapeutic monoclonal antibodies  · 30. June 2021

SYnabs generate therapeutic monoclonal antibodies against CC chemokine receptors thanks to modified peptides, DNA and cell immunization strategies

Membrane functional antibodies : depleting, blocking, neutralizing, agonist and antagonist · 09. April 2021

To address all B cell depletion needs, SYnAbs has developed monoclonal antibody references, which exhibit the ability to deplete murine or rat B cells in vivo, providing a valuable research tool for its biotech and pharma partners.